10-Q: BNB Plus Shifts to Digital Assets, Reports Q1 Loss

BNB Plus Corp. reports a significant net loss in Q1 2026, driven by its strategic pivot to a digital asset treasury strategy and associated fair value losses on digital assets.

Summary

• The company has undergone a strategic pivot to become a digital asset treasury (DAT) company, adopting BNB as its primary reserve asset, and is winding down or exiting legacy businesses.
• A significant workforce reduction of 16 employees (approximately 60%) was substantially completed by December 31, 2025, incurring pre-tax charges of $1.2 million in the quarter.
• Net loss for the three months ended December 31, 2025, was $18.61 million, a substantial increase from $2.67 million for the same period in 2024.
• Total revenues decreased by 35% to $565,394 for the three months ended December 31, 2025, compared to $870,291 in the prior year.
• Selling, general and administrative expenses surged by 420% to $13.35 million, primarily due to $9.42 million in consulting expenses, including $8.83 million for warrants issued to strategic consultants.
• The company recorded losses from fair value measurement of digital assets of $1.73 million and investment in digital asset trust of $3.48 million.
• A private placement in October 2025 raised $24.9 million in net proceeds, consisting of cash, USDC, and OBNB Trust Units.
• A material weakness in internal control over financial reporting was identified related to the preparation and review of inputs for fair value calculations, specifically warrant modifications.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a high-risk, transformative period. While the capital raise provides liquidity for the new digital asset strategy, the substantial net loss, significant fair value losses on digital assets, and the identified material weakness in internal controls indicate considerable operational and financial challenges during this strategic pivot.

Positives

• Successfully completed a private placement in October 2025, raising $24.9 million in net proceeds, providing capital for the new BNB Strategy.
• Management estimates sufficient cash and liquid cryptocurrency to fund operations for the next twelve months.
• Product revenues increased by 12% to $555,093 for the three months ended December 31, 2025, driven by increased sales to a large-scale DNA manufacturing customer.
• A significant workforce reduction of 60% was implemented as part of a restructuring plan to reduce overall operating expenses.
• Entered into a new, smaller corporate headquarters lease effective February 1, 2026, with significantly reduced monthly payments of $8,665 compared to the previous $52,440.

Negatives

• Net loss increased dramatically to $18.61 million for the three months ended December 31, 2025, from $2.67 million in the prior year, representing a 596% increase.
• Total revenues decreased by 35% year-over-year, primarily due to a 97% decrease in service revenues as legacy businesses are wound down.
• Gross profit decreased by 48% to $315,357, and the gross profit percentage declined from 70% to 56% due to a change in product mix.
• Selling, general and administrative expenses soared by 420% to $13.35 million, largely due to one-time consulting expenses and warrant issuances related to the digital asset strategy.
• Significant losses were incurred from the fair value measurement of digital assets ($1.73 million) and investment in digital asset trust ($3.48 million).
• Negative operating cash flow increased to $5.55 million for the quarter, up from $3.34 million in the prior year.
• The company has an accumulated deficit of $397.79 million as of December 31, 2025, indicating historical and ongoing financial challenges.
• A material weakness in internal control over financial reporting was identified related to fair value calculations for warrant modifications.

Risks

• Expectations of future revenues, expenditures, capital, or other funding requirements may not be met.
• The adequacy of cash and working capital to fund present and planned operations and growth is uncertain.
• The need for additional financing may require the issuance of additional shares of common stock, preferred stock, or other debt or equity securities, leading to stockholder dilution.
• Failure to realize the anticipated benefits of the digital asset treasury strategy.
• Risks related to the company's ability to raise and deploy capital effectively.
• Risks related to an unproven BNB yield generation strategy.
• The price of common stock may be highly correlated to the price of the digital assets held, exposing investors to cryptocurrency market volatility.
• Increased competition in the industries in which the company does and will operate.
• Risks relating to the treatment of cryptocurrency assets for U.S. and foreign tax purposes.
• Risks related to the unknown returns that the BNB Strategy will generate.
• The highly volatile nature of the price of BNB and other cryptocurrencies.
• Significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally.
• Risks relating to market volatility, cybersecurity, and custody of digital assets, potential changes in laws or accounting standards relating to cryptocurrency, and regulatory developments affecting BNB.
• The possibility that current holdings of BNB and/or OBNB Trust Units could subject the company to additional regulation, including classification as an investment company under the Investment Company Act, which would make it impractical to continue segments of the business.
• A material weakness in internal control over financial reporting related to the controls around the preparation and review of inputs utilized in fair value calculations, specifically as it related to warrant modifications.

Future Outlook

The company plans to strategically accumulate BNB and utilize it as a productive treasury asset to produce yield via Binance native and other decentralized finance (DeFi) opportunities. It intends to pursue opportunities to sell OBNB Trust Units for cash to purchase additional BNB or access the underlying BNB assets to further its BNB Strategy. Management estimates sufficient cash and liquid cryptocurrency to fund operations for the next twelve months. The company does not believe it will need to sell its Digital Asset Treasury within the next twelve months to meet working capital requirements, though it may engage in transactions as part of treasury management. Approximately $138,000 in additional workforce reduction charges are expected in the second quarter of fiscal 2026. The LineaRx business strategy is to continue advancing nucleic acid production solutions to support potential future sale and/or licensing of the business or its technology solutions to a third-party.

Management Comments

• "We estimate that we will have sufficient cash and cash equivalents, as well as liquid cryptocurrency to fund operations for the next twelve months from the date of filing these financial statements."
• "Our digital asset, as well as our investment in digital asset trust are considered longer-term investments (Digital asset treasury) and we do not believe we will need to sell our Digital asset treasury within the next twelve months to meet our working capital requirements, although we may from time to time sell or engage in other transactions with respect to our Digital asset treasury as part of our treasury management operations."
• "We are committed to maintaining a strong internal control environment and implementing measures designed to help ensure that this material weakness is remediated as soon as possible."

Industry Context

StockSavvy.ai notes that BNB Plus Corp.'s aggressive pivot to a digital asset treasury strategy, particularly focusing on BNB and DeFi yield generation, aligns with a growing trend among some companies to integrate cryptocurrency into their balance sheets and treasury operations. This move, however, introduces significant exposure to the highly volatile cryptocurrency market, contrasting with traditional corporate treasury management. The continued development of its LineaRx biopharmaceutical segment, while secondary to the new digital asset focus, positions the company in two distinct, high-growth but high-risk sectors.

Comparison to Industry Standards

• The filing does not provide specific comparable companies or projects for its new digital asset treasury strategy or its LineaRx biopharmaceutical segment, making direct industry comparisons challenging.
• The significant losses from fair value measurement of digital assets and the overall net loss indicate a challenging initial period for the new strategy, which is not uncommon in the highly volatile and speculative cryptocurrency market, where such fluctuations are inherent.
• The 60% workforce reduction and exit from legacy businesses suggest a drastic restructuring, which can be a sign of distress or a bold strategic realignment, a move often seen in companies undergoing significant strategic shifts in highly competitive or evolving industries.
• The identified material weakness in internal controls related to fair value calculations for warrant modifications is a concern that needs to be addressed to meet industry best practices for financial reporting and investor confidence.

Management Changes

Corporate Governance

Legal Proceedings

• No pending litigation involving the company at this time.

Related Party Transactions

• Strategic Digital Assets Services Agreement with Cypress LLC (a related party, with affiliates Joshua Kruger and Patrick Horsman) for discretionary asset management services. The agreement includes a fixed-rate management fee (1/12 of 1.25% per annum of net asset value) and an incentive fee (10% on net returns exceeding a high-water mark). No expenses were incurred under this agreement during the three months ended December 31, 2025.
• Strategic Advisor Agreement with Cypress Management LLC (a related party, with affiliates Joshua Kruger and Patrick Horsman) for strategic advice and technical advisory services. The company pays a monthly fee of $60,000 and issued five-year Advisory Warrants to purchase 1,986,634 shares of common stock at $3.82 per share. $180,000 in fees and $7,985,569 for the fair value of Advisory Warrants were recorded as consulting expense for the quarter.
• Patrick Horsman, Chief Investment Officer and an affiliate of Cypress LLC and Cypress Management LLC, receives monthly consulting compensation of $29,167. $111,616 in consulting and travel expenses were incurred under this agreement for the quarter.
• Accounts payable includes $89,167 related to related parties at December 31, 2025.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from potential future equity issuances and warrant exercises. Exposure to the high volatility of digital assets introduces substantial investment risk. The strategic pivot could lead to long-term value creation if successful, but the current quarter shows substantial losses.
• **Employees:** Experienced a significant workforce reduction (60%), impacting 16 employees, as part of the restructuring. Remaining employees are focused on the new digital asset strategy and the LineaRx segment.
• **Customers (LineaRx):** The company continues to focus on its nucleic acid production solutions, with product revenues increasing in this segment, suggesting continued service for these customers.
• **Creditors:** The accumulated deficit and recurring net losses indicate financial strain, although the recent capital raise provides short-term liquidity to manage operations.
• **Management:** New employment agreements for the CEO and CFO, including bonuses and stock options, aim to align their incentives with the company's strategic goals. A new CIO has been appointed to lead the digital asset strategy.

Next Steps

• Implement the BNB Strategy, including staking, restaking, liquid staking, and participation in other Binance ecosystem and DeFi yield opportunities.
• Pursue opportunities to sell OBNB Trust Units for cash to purchase additional BNB or access underlying BNB assets.
• Continue advancing nucleic acid production solutions for the LineaRx business to support potential future sale and/or licensing.
• Remediate the material weakness in internal control over financial reporting related to fair value calculations for warrant modifications.
• Incur approximately $138,000 in additional workforce reduction charges during the second quarter of fiscal 2026.
• James Haft's initial option grant will vest in four equal installments on May 2, 2026, August 2, 2026, November 2, 2026, and February 2, 2027.

Key Dates

Recommendation

The company is undergoing a radical strategic pivot into the highly speculative and volatile digital asset space, which is an unproven strategy for a publicly traded company of this nature. The substantial net loss, significant fair value losses on digital assets, and the identified material weakness in internal controls related to complex financial instruments (warrants) present considerable risks. While a capital raise provides some liquidity, the long-term viability and profitability of the BNB Strategy are highly uncertain, and the company's legacy biopharmaceutical business is being de-emphasized or wound down. This combination of factors suggests a high-risk investment with significant downside potential in the near to medium term.

Keywords

BNB Plus Corp., BNBX, Digital Asset Treasury, Cryptocurrency, BNB, Binance, DeFi, LineaRx, DNA Production, Gene Therapy, mRNA, SEC Filing, 10-Q, Financial Results, Q1 2026, Stock Split, Private Placement, Warrants, Corporate Restructuring, Workforce Reduction, Internal Controls, Market Risk